Category: Programme 1 – ThARGET

The SIRIC ILIAD Partners and Patient Representatives Committee met on 11 September to present its mid-term review. On 11 September

FICTIoN Cohort: Radiomic analyses of 18FDG PET and correlation with histology Type of study: Single-centre study Pathology: Triple-negative breast cancer,

The TLX102 treatment, resulting from the collaboration between Telix Pharmaceuticals (Australia), Osaka University (Japan) and the SIRIC ILIAD nuclear medicine

  The SIRIC ILIAD is organising its 3rd scientific day on 16 October 2020 at the dental faculty of the

EPICURE Cohort: Characterisation of tumour heterogeneity using Radiomics Type of study: Single-centre study Pathology: Breast cancer in first metastatic recurrence

During the annual meeting of the Society of Nuclear Medicine & Molecular Imaging SNMMI 2020 annual meeting in July, the

Predicting the effectiveness of second-line metastatic hormone therapy Type of study: Multicentre study Pathology: Metastatic breast cancer, HER2 negative Investigatr

Due to the Covid-19 pandemic, ISI NucMed originally scheduled for 8-10 June 2020 is postponed to june 28-30th 2021. Over

Immuno-PET optimization protocol: anti-ACE pre-targeting Type of study: Feasibility study Pathology: HER2 negative, ACE positive metastatic breast cancer Investigator :

Due to COVID crisis, the workshop is postponed to June 1st 2021. This international symposium will deal with different aspects